Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Last Updated: March 26, 2023

Details for Patent: 8,754,072

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,754,072 protect, and when does it expire?

Patent 8,754,072 protects RUBRACA and is included in one NDA.

This patent has sixty-two patent family members in thirty countries.

Summary for Patent: 8,754,072

Title:	Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[- 5,4,3-cd]indol-6-one
Abstract:	The present invention relates to novel polymorphic forms of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[- 5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity including the disease condition such as cancer.
Inventor(s):	Basford; Patricia Ann (Sandwich, GB), Campeta; Anthony Michael (Ledyard, CT), Gillmore; Adam (Sandwich, GB), Jones; Matthew Cameron (Sandwich, GB), Kougoulos; Eleftherios (Morrisville, NC), Luthra; Suman (Groton, CT), Walton; Robert (Sandwich, GB)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	13/522,549
Patent Claim Types: see list of patent claims	Compound; Composition;

Drugs Protected by US Patent 8,754,072

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Clovis Oncology Inc	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-001	Dec 19, 2016		RX	Yes	No	See Plans and Pricing	See Plans and Pricing	Y	Y			See Plans and Pricing
Clovis Oncology Inc	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-003	May 1, 2017		RX	Yes	No	See Plans and Pricing	See Plans and Pricing	Y	Y			See Plans and Pricing
Clovis Oncology Inc	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-002	Dec 19, 2016		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing	Y	Y			See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 8,754,072

PCT Information
PCT Filed	February 10, 2011	PCT Application Number:	PCT/IB2011/050571
PCT Publication Date:	August 18, 2011	PCT Publication Number:	WO2011/098971

International Family Members for US Patent 8,754,072

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	080164	See Plans and Pricing
Argentina	109356	See Plans and Pricing
Australia	2011213944	See Plans and Pricing
Brazil	112012019050	See Plans and Pricing
Canada	2787881	See Plans and Pricing
Canada	3024216	See Plans and Pricing
China	102884066	See Plans and Pricing
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic

Colorcon

McKesson

Merck

Moodys

Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.